| 63.54 5.46 (9.4%) | 06-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 75.33 |
1-year : | 87.99 |
| Resists | First : | 64.5 |
Second : | 75.33 |
| Pivot price | 57.28 |
|||
| Supports | First : | 49.89 |
Second : | 40.86 |
| MAs | MA(5) : | 58.49 |
MA(20) : | 55.73 |
| MA(100) : | 66.52  |
MA(250) : | 99.35 |
|
| MACD | MACD : | 2.1 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 65.9 |
D(3) : | 60.1 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 170.86 | Low : | 32.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ WGS ] has closed below upper band by 4.8%. Bollinger Bands are 41.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 64.58 - 64.84 | 64.84 - 65.09 |
| Low: | 57.91 - 58.18 | 58.18 - 58.43 |
| Close: | 63.08 - 63.53 | 63.53 - 63.96 |
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.
Wed, 24 Jun 2026
WGS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages WGS Investors With Losses to Contact the Firm - The Globe and Mail
Wed, 24 Jun 2026
Did You Lose Money on GeneDx Holdings Corp. (WGS)? Levi & Korsinsky Urges Investors to Act Before August 3, 2026 - ACCESS Newswire
Wed, 24 Jun 2026
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings - GlobeNewswire
Wed, 24 Jun 2026
Lost Money on GeneDx Holdings Corp. (WGS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - PR Newswire
Wed, 24 Jun 2026
GENEDX HOLDINGS CORP. INVESTORS WITH LOSSES HAVE UNTIL - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 30 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 114.6 (%) |
| Shares Short | 4,570 (K) |
| Shares Short P.Month | 4,220 (K) |
| EPS | -2.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.53 |
| Profit Margin | -17.6 % |
| Operating Margin | -25.7 % |
| Return on Assets (ttm) | -4.4 % |
| Return on Equity (ttm) | -30.5 % |
| Qtrly Rev. Growth | 17.3 % |
| Gross Profit (p.s.) | 10.37 |
| Sales Per Share | 14.91 |
| EBITDA (p.s.) | -0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -23.89 |
| PEG Ratio | 0 |
| Price to Book value | 6.02 |
| Price to Sales | 4.26 |
| Price to Cash Flow | -202.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|